S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in
NASDAQ:LMNX

Luminex Stock Forecast, Price & News

$32.99
+2.94 (+9.78 %)
(As of 02/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$29.93
Now: $32.99
$35.07
50-Day Range
$25.59
MA: $27.99
$30.07
52-Week Range
$20.61
Now: $32.99
$41.69
Volume4.78 million shs
Average Volume652,962 shs
Market Capitalization$1.53 billion
P/E Ratio84.59
Dividend Yield1.33%
Beta0.61
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; FlowSight Imaging Flow cytometer; ImageStream System; CellStream Flow Cytometer; Guava easyCyte line; and Muse Cell Analyzer. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
Luminex logo

Headlines

Luminex receives BARDA funding - Seeking Alpha
February 19, 2021 |  seekingalpha.com
Luminex receives BARDA funding
February 19, 2021 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:LMNX
CUSIP55027E10
Phone512-219-8020
Employees1,247
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$334.64 million
Cash Flow$0.52 per share
Book Value$10.32 per share

Profitability

Net Income$-3,840,000.00

Miscellaneous

Market Cap$1.53 billion
Next Earnings Date5/3/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.78 out of 5 stars

Medical Sector

36th out of 1,957 stocks

Surgical & Medical Instruments Industry

7th out of 168 stocks

Analyst Opinion: 2.5Community Rank: 2.0Dividend Strength: 0.8Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$32.99
+2.94 (+9.78 %)
(As of 02/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LMNX News and Ratings via Email

Sign-up to receive the latest news and ratings for LMNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Luminex (NASDAQ:LMNX) Frequently Asked Questions

Is Luminex a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Luminex stock.
View analyst ratings for Luminex
or view top-rated stocks.

What stocks does MarketBeat like better than Luminex?

Wall Street analysts have given Luminex a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Luminex wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Luminex's next earnings date?

Luminex is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for Luminex
.

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) issued its earnings results on Sunday, February, 7th. The medical instruments supplier reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.13 by $0.12. The medical instruments supplier earned $111.39 million during the quarter, compared to the consensus estimate of $104.57 million. Luminex had a net margin of 4.60% and a trailing twelve-month return on equity of 3.75%. The company's revenue for the quarter was up 23.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.07 earnings per share.
View Luminex's earnings history
.

How has Luminex's stock been impacted by COVID-19 (Coronavirus)?

Luminex's stock was trading at $27.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LMNX shares have increased by 21.7% and is now trading at $32.99.
View which stocks have been most impacted by COVID-19
.

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex declared a quarterly dividend on Tuesday, February 9th. Shareholders of record on Thursday, March 25th will be given a dividend of $0.10 per share on Thursday, April 15th. This represents a $0.40 annualized dividend and a dividend yield of 1.21%. The ex-dividend date of this dividend is Wednesday, March 24th.
View Luminex's dividend history
.

Is Luminex a good dividend stock?

Luminex pays an annual dividend of $0.40 per share and currently has a dividend yield of 1.33%.
View Luminex's dividend history.

What guidance has Luminex issued on next quarter's earnings?

Luminex issued an update on its FY 2021 After-Hours earnings guidance on Monday, February, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $480-480 million, compared to the consensus revenue estimate of $474.36 million.

What price target have analysts set for LMNX?

1 analysts have issued 1 year target prices for Luminex's shares. Their forecasts range from $38.00 to $38.00. On average, they expect Luminex's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 15.2% from the stock's current price.
View analysts' price targets for Luminex
or view top-rated stocks among Wall Street analysts.

Who are Luminex's key executives?

Luminex's management team includes the following people:
  • Mr. Nachum Shamir, Chairman, CEO & Pres (Age 67, Pay $1.36M)
  • Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 59, Pay $630.63k)
  • Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 53, Pay $539.33k)
  • Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 51, Pay $500.04k)
  • Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 59, Pay $484.9k)
  • Mrs. Kendel B. Martin CPA, VP of Accounting
  • Jeff Christensen, Sr. Director of Investor Relations
  • Mr. Eric S. Shapiro, Sr. VP of Global Marketing (Age 57)
  • Ms. Nancy M. Fairchild, Sr. VP of HR (Age 67)
  • Dr. Charles J. Collins, Sr. VP of R&D (Age 44)

What is Nachum “Homi” Shamir's approval rating as Luminex's CEO?

53 employees have rated Luminex CEO Nachum “Homi” Shamir on Glassdoor.com. Nachum “Homi” Shamir has an approval rating of 87% among Luminex's employees.

Who are some of Luminex's key competitors?

What other stocks do shareholders of Luminex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include NVIDIA (NVDA), Baidu (BIDU), Cisco Systems (CSCO), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Micron Technology (MU), Square (SQ), Marvell Technology Group (MRVL), AbbVie (ABBV) and CRISPR Therapeutics (CRSP).

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Who are Luminex's major shareholders?

Luminex's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.55%), Dimensional Fund Advisors LP (3.96%), Copeland Capital Management LLC (2.98%), Renaissance Technologies LLC (1.41%), Bank of New York Mellon Corp (1.27%) and Northern Trust Corp (1.26%). Company insiders that own Luminex stock include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild, Randall Myers, Richard W Rew II and Stephen L Eck.
View institutional ownership trends for Luminex
.

Which major investors are selling Luminex stock?

LMNX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Robeco Institutional Asset Management B.V., Dimensional Fund Advisors LP, Public Sector Pension Investment Board, Wells Fargo & Company MN, Russell Investments Group Ltd., Aviva PLC, and Glenmede Trust Co. NA. Company insiders that have sold Luminex company stock in the last year include G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild, Randall Myers, and Richard W Rew II.
View insider buying and selling activity for Luminex
or view top insider-selling stocks.

Which major investors are buying Luminex stock?

LMNX stock was acquired by a variety of institutional investors in the last quarter, including Copeland Capital Management LLC, BlackRock Inc., Tamarack Advisers LP, Frontier Capital Management Co. LLC, Investment Management of Virginia LLC, Amundi Pioneer Asset Management Inc., Morgan Stanley, and Crawford Investment Counsel Inc.. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II, Nachum Shamir, and Stephen L Eck.
View insider buying and selling activity for Luminex
or or view top insider-buying stocks.

How do I buy shares of Luminex?

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Luminex's stock price today?

One share of LMNX stock can currently be purchased for approximately $32.99.

How much money does Luminex make?

Luminex has a market capitalization of $1.53 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.

How many employees does Luminex have?

Luminex employs 1,247 workers across the globe.

What is Luminex's official website?

The official website for Luminex is www.luminexcorp.com.

Where are Luminex's headquarters?

Luminex is headquartered at 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727.

How can I contact Luminex?

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]


This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.